2025-524043-12-00
Recruiting
Phase 1
A study to learn more about the safety and effects of a new blood-thinning medicine, given alone and together with another blood-thinner, in healthy adults
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Bayer AG
- Enrollment
- 72
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Therapeutic Area Head
Scientific
Bayer AG
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours2023-505006-41-00AstraZeneca AB100
Recruiting
Not Applicable
An observational study to verify the safety and effectiveness of treatment using organic iodine + MD(alpha) for patients with advanced cancer (stage 3 or later) using standard and advanced test indicatorsCancerjRCT103026001610
Recruiting
Not Applicable
An observational study to verify the safety and efficacy of treatment with JWT for patients with advanced cancer (stage 3 or later) using standard and advanced testing indicatorsCancerjRCT103026001110
Recruiting
Phase 1
A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemotherapy, as the first treatment option for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer.2023-504949-31-00AstraZeneca AB37
Recruiting
Phase 1
A study to investigate the safety and tolerability of SDL-M1 nanoparticles in healthy volunteers2024-518889-27-00SmartDyeLivery GmbH48